Research Article
Onychomycosis in Psoriatic Patients with Nail Disorders: Aetiological Agents and Immunosuppressive Therapy
Table 4
Drugs used to treat patients with psoriatic disease with and without onychomycosis.
| | Drugs | Number of patients, n (%) | With onychomycosis, n (%) | Without onychomycosis, n (%) |
| | Acitretin | 3 (7.89) | 1 (2.63) | 2 (5.26) | | Methotrexate | 14 (36.82) | 13 (34.19) | 1 (2.63) | | Adalimumab | 4 (10.52) | 3 (7.89) | 1 (2.63) | | Etanercept | 3 (7.89) | 1 (2.63) | 2 (5.26) | | Infliximab | 1 (2.63) | 1 (2.63) | 0 | | Secukinumab | 2 (2.63) | 0 | 2 (5.26) | | Golimumab | 2 (2.63) | 0 | 2 (5.26) | | Methotrexate + adalimumab | 2 (2.63) | 1 (2.63) | 1 (2.63) | | Methotrexate + etanercept | 2 (2.63) | 1 (2.63) | 1 (2.63) | | Methotrexate + infliximab | 2 (2.63) | 0 | 2 (5.26) | | None | 3 (7.89) | 1 (2.63) | 2 (5.26) | | Total | 38 (100) | 22 (57.86) | 16 (42.08) |
|
|
